These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24320787)

  • 21. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M; Tudor IC; Khanna S; Thipphawong J
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Buprenorphine 5, 10 and 20 μg/h transdermal patch: a guide to its use in chronic non-malignant pain.
    Plosker GL; Lyseng-Williamson KA
    CNS Drugs; 2012 Apr; 26(4):367-73. PubMed ID: 22369187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of analgesic effects of different initial doses of transdermal buprenorphine in the treatment of chronic pain in the elderly diagnosed with osteoarthritis.
    Widenka M; Leppert W
    J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transdermal buprenorphine in non-oncological moderate-to-severe chronic pain.
    Gatti A; Dauri M; Leonardis F; Longo G; Marinangeli F; Mammucari M; Sabato AF
    Clin Drug Investig; 2010; 30 Suppl 2():31-8. PubMed ID: 20670047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain.
    Ripa SR; McCarberg BH; Munera C; Wen W; Landau CJ
    Expert Opin Pharmacother; 2012 Jun; 13(9):1229-41. PubMed ID: 22409388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of transdermal buprenorphine patch in the elderly.
    Al-Tawil N; Odar-Cederlöf I; Berggren AC; Johnson HE; Persson J
    Eur J Clin Pharmacol; 2013 Feb; 69(2):143-9. PubMed ID: 22706617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study.
    Steiner D; Munera C; Hale M; Ripa S; Landau C
    J Pain; 2011 Nov; 12(11):1163-73. PubMed ID: 21807566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transdermal buprenorphine for the treatment of cancer pain: results from a multicenter, observational, post-marketing study in Spain (RELIEF study).
    Camps C; Casinello J; Virizuela JA; Escobar Y; Sanchez-Magro I; Stern A
    Pain Manag; 2011 Nov; 1(6):513-22. PubMed ID: 24645762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effectiveness and safety of transdermal buprenorphine for chronic pain treatment in the elderly: a prospective observational study].
    Muriel Villoria C; Pérez-Castejón Garrote JM; Sánchez Magro I; Neira Alvarez M
    Med Clin (Barc); 2007 Feb; 128(6):204-10. PubMed ID: 17335723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials.
    Yarlas A; Miller K; Wen W; Lynch SY; Ripa SR; Pergolizzi JV; Raffa RB
    Pain Pract; 2016 Mar; 16(3):345-58. PubMed ID: 25599968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R; Kayser H; Sittl R
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
    Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
    Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain].
    Tschirner M; Ritzdorf I; Brünjes R
    MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Transdermal buprenorphine for treatment of chronic tumor and non-tumor pain].
    Likar R; Griessinger N; Sadjak A; Sittl R
    Wien Med Wochenschr; 2003; 153(13-14):317-22. PubMed ID: 12924108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the efficacy and safety of transdermal buprenorphine patch to conventional analgesics after operative fixation of extra capsular fracture of proximal femur.
    Londhe SB; Patwardhan M; Shah RV; Desouza C; Oak M; Antao NA
    Injury; 2024 Jun; 55 Suppl 2():111395. PubMed ID: 39098786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain.
    Wolff RF; Aune D; Truyers C; Hernandez AV; Misso K; Riemsma R; Kleijnen J
    Curr Med Res Opin; 2012 May; 28(5):833-45. PubMed ID: 22443154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: a retrospective cohort study.
    Gallagher AM; Leighton-Scott J; van Staa TP
    Clin Ther; 2009 Aug; 31(8):1707-15. PubMed ID: 19808129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of transdermal buprenorphine in the management of children with cancer-related pain.
    Ruggiero A; Coccia P; Arena R; Maurizi P; Battista A; Ridola V; Attinà G; Riccardi R
    Pediatr Blood Cancer; 2013 Mar; 60(3):433-7. PubMed ID: 23034996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of Transdermal Buprenorphine Patches for the Treatment of Chronic Pain in a UK Observational Study.
    Serpell M; Tripathi S; Scherzinger S; Rojas-Farreras S; Oksche A; Wilson M
    Patient; 2016 Feb; 9(1):35-46. PubMed ID: 26547914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.